Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 5.7%

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) were down 5.7% on Friday . The company traded as low as $3.13 and last traded at $3.14. Approximately 390,099 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 1,605,249 shares. The stock had previously closed at $3.33.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. Truist Financial upped their target price on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, April 9th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a report on Monday, June 17th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $8.70.

Autolus Therapeutics Stock Up 4.5 %

The firm has a market cap of $925.82 million, a PE ratio of -2.92 and a beta of 2.02. The company has a 50-day simple moving average of $4.05 and a two-hundred day simple moving average of $5.32.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Friday, May 17th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.14). The company had revenue of $10.09 million for the quarter, compared to the consensus estimate of $50.00 million. During the same quarter in the prior year, the business earned ($0.23) earnings per share. As a group, equities analysts predict that Autolus Therapeutics plc will post -0.78 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Avoro Capital Advisors LLC purchased a new position in Autolus Therapeutics in the first quarter valued at approximately $78,765,000. Price T Rowe Associates Inc. MD raised its stake in shares of Autolus Therapeutics by 82.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after buying an additional 2,487,778 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Autolus Therapeutics during the 4th quarter valued at $11,793,000. Affinity Asset Advisors LLC grew its stake in shares of Autolus Therapeutics by 117.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company’s stock worth $21,532,000 after acquiring an additional 1,824,592 shares during the period. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Autolus Therapeutics in the 3rd quarter worth about $679,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.